Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, et al. (2016)
The Lancet Oncology 18(1): 132-142.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ; ;
Alle
Abstract / Bemerkung
Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease.
Erscheinungsjahr
Zeitschriftentitel
The Lancet Oncology
Band
18
Ausgabe
1
Seite(n)
132-142
ISSN
PUB-ID

Zitieren

Guinney J, Wang T, Laajala TD, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology. 2016;18(1):132-142.
Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., et al. (2016). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology, 18(1), 132-142. doi:10.1016/s1470-2045(16)30560-5
Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., et al. (2016). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology 18, 132-142.
Guinney, J., et al., 2016. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology, 18(1), p 132-142.
J. Guinney, et al., “Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data”, The Lancet Oncology, vol. 18, 2016, pp. 132-142.
Guinney, J., Wang, T., Laajala, T.D., Winner, K.K., Bare, J.C., Neto, E.C., Khan, S.A., Peddinti, G., Airola, A., Pahikkala, T., Mirtti, T., Yu, T., Bot, B.M., Shen, L., Abdallah, K., Norman, T., Friend, S., Stolovitzky, G., Soule, H., Sweeney, C.J., Ryan, C.J., Scher, H.I., Sartor, O., Xie, Y., Aittokallio, T., Zhou, F.L., Costello, J.C., Abdallah, K., Aittokallio, T., Airola, A., Anghe, C., Azima, H., Baertsch, R., Ballester, P.J., Bare, C., Bhandari, V., Bot, B.M., Dang, C.C., Dunbar, M.B.-N., Buchardt, A.-S., Buturovic, L., Cao, D., Chalise, P., Cho, J., Chu, T.-M., Coley, R.Y., Conjeti, S., Correia, S., Costello, J.C., Dai, Z., Dai, J., Dargatz, P., Delavarkhan, S., Deng, D., Dhanik, A., Du, Y., Elangovan, A., Ellis, S., Elo, L.L., Espiritu, S.M., Fan, F., Farshi, A.B., Freitas, A., Fridley, B., Friend, S., Fuchs, C., Gofer, E., Peddinti, G., Graw, S., Greiner, R., Guan, Y., Guinney, J., Guo, J., Gupta, P., Guyer, A.I., Han, J., Hansen, N.R., Chang, B.H.W., Hirvonen, O., Huang, B., Huang, C., Hwang, J., Ibrahim, J.G., Jayaswa, V., Jeon, J., Ji, Z., Juvvadi, D., Jyrkkiö, S., Kanigel-Winner, K., Katouzian, A., Kazanov, M.D., Khan, S.A., Khayyer, S., Kim, D., Golinska, A.K., Koestler, D., Kokowicz, F., Kondofersky, I., Krautenbacher, N., Krstajic, D., Kumar, L., Kurz, C., Kyan, M., Laajala, T.D., Laimighofer, M., Lee, E., Lesinski, W., Li, M., Li, Y., Lian, Q., Liang, X., Lim, M., Lin, H., Lin, X., Lu, J., Mahmoudian, M., Manshaei, R., Meier, R., Miljkovic, D., Mirtti, T., Mnich, K., Navab, N., Neto, E.C., Newton, Y., Norman, T., Pahikkala, T., Pal, S., Park, B., Patel, J., Pathak, S., Pattin, A., Ankerst, D.P., Peng, J., Petersen, A.H., Philip, R., Piccolo, S.R., Pölsterl, S., Polewko-Klim, A., Rao, K., Ren, X., Rocha, M., Rudnicki, W.R., Ryan, C.J., Ryu, H., Sartor, O., Scherb, H., Sehgal, R., Seyednasrollah, F., Shang, J., Shao, B., Shen, L., Sher, H., Shiga, M., Sokolov, A., Söllner, J.F., Song, L., Soule, H., Stolovitzky, G., Stuart, J., Sun, R., Sweeney, C.J., Tahmasebi, N., Tan, K.-T., Tomaziu, L., Usset, J., Vang, Y.S., Vega, R., Vieira, V., Wang, D., Wang, D., Wang, J., Wang, L., Wang, S., Wang, T., Wang, Y., Wolfinger, R., Wong, C., Wu, Z., Xiao, J., Xie, X., Xie, Y., Xin, D., Yang, H., Yu, N., Yu, T., Yu, X., Zahedi, S., Zanin, M., Zhang, C., Zhang, J., Zhang, S., Zhang, Y., Zhou, F.L., Zhu, H., Zhu, S., Zhu, Y.: Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology. 18, 132-142 (2016).
Guinney, Justin, Wang, Tao, Laajala, Teemu D, Winner, Kimberly Kanigel, Bare, J Christopher, Neto, Elias Chaibub, Khan, Suleiman A, Peddinti, Gopal, Airola, Antti, Pahikkala, Tapio, Mirtti, Tuomas, Yu, Thomas, Bot, Brian M, Shen, Liji, Abdallah, Kald, Norman, Thea, Friend, Stephen, Stolovitzky, Gustavo, Soule, Howard, Sweeney, Christopher J, Ryan, Charles J, Scher, Howard I, Sartor, Oliver, Xie, Yang, Aittokallio, Tero, Zhou, Fang Liz, Costello, James C, Abdallah, Kald, Aittokallio, Tero, Airola, Antti, Anghe, Catalina, Azima, Helia, Baertsch, Robert, Ballester, Pedro J, Bare, Chris, Bhandari, Vinayak, Bot, Brian M, Dang, Cuong C, Dunbar, Maria Bekker-Nielsen, Buchardt, Ann-Sophie, Buturovic, Ljubomir, Cao, Da, Chalise, Prabhakar, Cho, Junwoo, Chu, Tzu-Ming, Coley, R Yates, Conjeti, Sailesh, Correia, Sara, Costello, James C, Dai, Ziwei, Dai, Junqiang, Dargatz, Philip, Delavarkhan, Sam, Deng, Detian, Dhanik, Ankur, Du, Yu, Elangovan, Aparna, Ellis, Shellie, Elo, Laura L, Espiritu, Shadrielle M, Fan, Fan, Farshi, Ashkan B, Freitas, Ana, Fridley, Brooke, Friend, Stephen, Fuchs, Christiane, Gofer, Eyal, Peddinti, Gopalacharyulu, Graw, Stefan, Greiner, Russ, Guan, Yuanfang, Guinney, Justin, Guo, Jing, Gupta, Pankaj, Guyer, Anna I, Han, Jiawei, Hansen, Niels R, Chang, Billy HW, Hirvonen, Outi, Huang, Barbara, Huang, Chao, Hwang, Jinseub, Ibrahim, Joseph G, Jayaswa, Vivek, Jeon, Jouhyun, Ji, Zhicheng, Juvvadi, Deekshith, Jyrkkiö, Sirkku, Kanigel-Winner, Kimberly, Katouzian, Amin, Kazanov, Marat D, Khan, Suleiman A, Khayyer, Shahin, Kim, Dalho, Golinska, Agnieszka K, Koestler, Devin, Kokowicz, Fernanda, Kondofersky, Ivan, Krautenbacher, Norbert, Krstajic, Damjan, Kumar, Luke, Kurz, Christoph, Kyan, Matthew, Laajala, Teemu D, Laimighofer, Michael, Lee, Eunjee, Lesinski, Wojciech, Li, Miaozhu, Li, Ye, Lian, Qiuyu, Liang, Xiaotao, Lim, Minseong, Lin, Henry, Lin, Xihui, Lu, Jing, Mahmoudian, Mehrad, Manshaei, Roozbeh, Meier, Richard, Miljkovic, Dejan, Mirtti, Tuomas, Mnich, Krzysztof, Navab, Nassir, Neto, Elias C, Newton, Yulia, Norman, Thea, Pahikkala, Tapio, Pal, Subhabrata, Park, Byeongju, Patel, Jaykumar, Pathak, Swetabh, Pattin, Alejandrina, Ankerst, Donna P, Peng, Jian, Petersen, Anne H, Philip, Robin, Piccolo, Stephen R, Pölsterl, Sebastian, Polewko-Klim, Aneta, Rao, Karthik, Ren, Xiang, Rocha, Miguel, Rudnicki, Witold R., Ryan, Charles J, Ryu, Hyunnam, Sartor, Oliver, Scherb, Hagen, Sehgal, Raghav, Seyednasrollah, Fatemeh, Shang, Jingbo, Shao, Bin, Shen, Liji, Sher, Howard, Shiga, Motoki, Sokolov, Artem, Söllner, Julia F, Song, Lei, Soule, Howard, Stolovitzky, Gustavo, Stuart, Josh, Sun, Ren, Sweeney, Christopher J, Tahmasebi, Nazanin, Tan, Kar-Tong, Tomaziu, Lisbeth, Usset, Joseph, Vang, Yeeleng S, Vega, Roberto, Vieira, Vitor, Wang, David, Wang, Difei, Wang, Junmei, Wang, Lichao, Wang, Sheng, Wang, Tao, Wang, Yue, Wolfinger, Russ, Wong, Chris, Wu, Zhenke, Xiao, Jinfeng, Xie, Xiaohui, Xie, Yang, Xin, Doris, Yang, Hojin, Yu, Nancy, Yu, Thomas, Yu, Xiang, Zahedi, Sulmaz, Zanin, Massimiliano, Zhang, Chihao, Zhang, Jingwen, Zhang, Shihua, Zhang, Yanchun, Zhou, Fang Liz, Zhu, Hongtu, Zhu, Shanfeng, and Zhu, Yuxin. “Prediction of overall survival for patients with metastatic castration-resistant prostate cancer. Development of a prognostic model through a crowdsourced challenge with open clinical trial data”. The Lancet Oncology 18.1 (2016): 132-142.

33 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.
Song J, Tian J, Zhang L, Qu X, Qian W, Zheng B, Zhang L, Zhao J, Niu M, Zhou M, Cui L, Liu Y, Zhao M., Eur Radiol 29(5), 2019
PMID: 30643941
Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.
Vossen DM, Verhagen CVM, van der Heijden M, Essers PBM, Bartelink H, Verheij M, Wessels LFA, van den Brekel MWM, Vens C., Cancers (Basel) 11(4), 2019
PMID: 30934880
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.
Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y., Cancer Inform 18(), 2019
PMID: 31057324
Crowdsourcing in medical research: concepts and applications.
Tucker JD, Day S, Tang W, Bayus B., PeerJ 7(), 2019
PMID: 30997295
Metastatic Prostate Cancer.
Sartor O, de Bono JS., N Engl J Med 378(7), 2018
PMID: 29412780
A community approach to mortality prediction in sepsis via gene expression analysis.
Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, Bermejo-Martin JF, Almansa R, Tamayo E, Davenport EE, Burnham KL, Hinds CJ, Knight JC, Woods CW, Kingsmore SF, Ginsburg GS, Wong HR, Parnell GP, Tang B, Moldawer LL, Moore FE, Omberg L, Khatri P, Tsalik EL, Mangravite LM, Langley RJ., Nat Commun 9(1), 2018
PMID: 29449546
Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.
Sade JP, Báez CAV, Greco M, Martínez CH, Avitia MÁÁ, Palazzo C, Toriz NH, Trujillo PIB, Bastos DA, Schutz FA, Bella S, Nogueira L, Shore ND., Med Oncol 35(4), 2018
PMID: 29556815
Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children.
Bonifacio E, Beyerlein A, Hippich M, Winkler C, Vehik K, Weedon MN, Laimighofer M, Hattersley AT, Krumsiek J, Frohnert BI, Steck AK, Hagopian WA, Krischer JP, Lernmark Å, Rewers MJ, She JX, Toppari J, Akolkar B, Oram RA, Rich SS, Ziegler AG, TEDDY Study Group., PLoS Med 15(4), 2018
PMID: 29614081
Alternative models for sharing confidential biomedical data.
Guinney J, Saez-Rodriguez J., Nat Biotechnol 36(5), 2018
PMID: 29734317
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G., BJU Int 122(4), 2018
PMID: 29802777
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S., Leukemia 32(7), 2018
PMID: 29925907
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.
Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O., Future Oncol 14(24), 2018
PMID: 29925281
Time to really share real-world data?
Graham S, McDonald L, Wasiak R, Lees M, Ramagopalan S., 2018
PMID: PPR45021
Time to really share real-world data?
Graham S, McDonald L, Wasiak R, Lees M, Ramagopalan S., F1000Res 7(), 2018
PMID: 30364186
Cancer Informatics in 2017: A New Beginning and a Bright Future.
Warner JL, Patt DA, Section Editors for the IMIA Yearbook Section on Cancer Informatics., Yearb Med Inform 27(1), 2018
PMID: 30157527
Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
Wang M, Lindberg J, Klevebring D, Nilsson C, Lehmann S, Grönberg H, Rantalainen M., J Natl Cancer Inst 110(10), 2018
PMID: 29506270
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
Seyednasrollah F, Mahmoudian M, Rautakorpi L, Hirvonen O, Laitinen T, Jyrkkiö S, Elo LL., Eur Urol 71(5), 2017
PMID: 28189430
Advantages of a Truly Open-Access Data-Sharing Model.
Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ., N Engl J Med 376(12), 2017
PMID: 28328337
Identification of genes associated with castration‑resistant prostate cancer by gene expression profile analysis.
Huang CG, Li FX, Pan S, Xu CB, Dai JQ, Zhao XH., Mol Med Rep 16(5), 2017
PMID: 28901445
Community mining of open clinical trial data.
Laajala TD, Guinney J, Costello JC., Oncotarget 8(47), 2017
PMID: 29137211
Current and emerging trends in prostate cancer immunotherapy.
Schatz A, Mian BM., Asian J Androl (), 2017
PMID: 29176187
Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients.
Wengel Mogensen S, H Petersen A, Buchardt AS, Hansen NR., F1000Res 5(), 2016
PMID: 28105311
An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients.
Meier R, Graw S, Usset J, Raghavan R, Dai J, Chalise P, Ellis S, Fridley B, Koestler D., F1000Res 5(), 2016
PMID: 28413609
Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients.
Pölsterl S, Gupta P, Wang L, Conjeti S, Katouzian A, Navab N., F1000Res 5(), 2016
PMID: 28713544

60 References

Daten bereitgestellt von Europe PubMed Central.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ., J. Clin. Oncol. 32(7), 2014
PMID: 24449231
Challenges: Crowdsourced solutions.
Bender E., Nature 533(7602), 2016
PMID: 27167394
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators., Lancet Oncol. 14(8), 2013
PMID: 23742877
Abiraterone and increased survival in metastatic prostate cancer.
Berruti A, Pia A, Terzolo M., N. Engl. J. Med. 365(8), 2011
PMID: 21864182
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators, Alasino C, Bella S, Carraro S, Geist M, Abdi E, Begbie S, Briscoe K, Davis I, Dowling A, Ganju V, Gurney H, Hovey E, Ng S, Nottage M, Rosenthal M, Stockler M, Tan T, Wong S, Young R, Krainer M, Loidl W, Machiels J, Mebis J, Renard V, Dumez H, Van Aelst F, Werbrouck P, Ellard S, Joshua A, Karakiewicz P, Lacombe L, Lattouf JB, Michels J, Mukherjee S, Ruether D, Venner P, Winquist E, Wood L, Aren O, Gonzalez P, Pastor P, Baumgaertner I, Beuzeboc P, Bompas E, Boyle H, Colombel M, Delva R, Eymard J, Gravis G, Guillot A, Houede N, Joly F, Kaphan R, Loriot Y, Oudard S, Priou F, Tartas S, Theodore C, Tourani JM, Voog E, Bogemann M, Hadaschik B, Hammerer P, Heidenreich A, Holzer W, Merseburger A, Stenzl A, Steuber T, Suttmann H, Trojan L, Wirth M, Cerbone L, Conte P, Passalacqua R, Tucci M, Gerritsen W, Jassem J, Kalinka-Warzocha E, Olubiec J, De Bruyne R, Malan J, Vorobiof D, Bellmunt J, Carles J, Duran I, Font A, Gil-Bazo I, Maroto J, Bahl A, Choudhury A, Hoskin P, James N, Jones R, Mazhar D, O'Sullivan J, Payne H, Pedley I, Protheroe A, Waxman J, Zivi A, Alexander B, Appleman L, Aragon-Ching J, Arrowsmith E, Assikis V, Beer T, Berry W, Bolger G, Bryce A, Bubley G, Chatta G, Denmeade S, Deshpande H, Dorff T, Galsky M, George D, Giudice R, Glode M, Golshayan AR, Goodman O, Graff J, Green L, Green R, Haas N, Higano C, Hutson T, Kohli M, Liu G, May J, Mendelson D, Picus J, Pili R, Posadas E, Redfern C, Rettig M, Ryan C, Scholz M, Sharifi N, Sosman J, Srinivas S, Tagawa S, Twardowski P, Vaishampayan U, Wong YN., N. Engl. J. Med. 367(13), 2012
PMID: 22894553
Crowdsourcing biomedical research: leveraging communities as innovation engines.
Saez-Rodriguez J, Costello JC, Friend SH, Kellen MR, Mangravite L, Meyer P, Norman T, Stolovitzky G., Nat. Rev. Genet. 17(8), 2016
PMID: 27418159
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G., J. Clin. Oncol. 29(16), 2011
PMID: 21483004
Data Sharing.
Longo DL, Drazen JM., N. Engl. J. Med. 374(3), 2016
PMID: 26789876
A Global, Neutral Platform for Sharing Trial Data.
Bierer BE, Li R, Barnes M, Sim I., N. Engl. J. Med. 374(25), 2016
PMID: 27168194
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.
Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Borresen-Dale AL., Sci Transl Med 5(181), 2013
PMID: 23596205
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators., Lancet 376(9747), 2010
PMID: 20888992
Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection.
Ewing AD, Houlahan KE, Hu Y, Ellrott K, Caloian C, Yamaguchi TN, Bare JC, P'ng C, Waggott D, Sabelnykova VY; ICGC-TCGA DREAM Somatic Mutation Calling Challenge participants, Kellen MR, Norman TC, Haussler D, Friend SH, Stolovitzky G, Margolin AA, Stuart JM, Boutros PC, Xi L, Dewal N, Fan Y, Wang W, Wheeler D, Wilm A, Ting GH, Li C, Bertrand D, Nagarajan N, Chen QR, Hsu CH, Hu Y, Yan C, Kibbe W, Meerzaman D, Cibulskis K, Rosenberg M, Bergelson L, Kiezun A, Radenbaugh A, Sertier AS, Ferrari A, Tonton L, Bhutani K, Hansen NF, Wang D, Song L, Lai Z, Liao Y, Shi W, Carbonell-Caballero J, Dopazo J, Lau CC, Guinney J., Nat. Methods 12(7), 2015
PMID: 25984700
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K, Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW., J. Clin. Oncol. 31(14), 2013
PMID: 23569308
Avoiding Data Dumpsters--Toward Equitable and Useful Data Sharing.
Merson L, Gaye O, Guerin PJ., N. Engl. J. Med. 374(25), 2016
PMID: 27168351
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ., J. Clin. Oncol. 21(7), 2003
PMID: 12663709
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M., Clin. Cancer Res. 13(21), 2007
PMID: 17975152
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tanimoto T, Hori A, Kami M., N. Engl. J. Med. 363(20), 2010
PMID: 21067392
Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators, Begbie S, Bonaventura A, Boyce A, Chua W, de Souza P, Davis I, Gardiner F, Guminski A, Gurney H, Hovey E, Mainwaring P, Marx G, Mathlum M, Parente P, Parnis F, Pook D, Rosenthal M, Shapiro J, Toner G, Warren M, Wong S, Woo H, Janetschek G, Krainer M, Loidl W, Schmeller N, Mebis J, Renard V, Tombal B, Van Poppel H, Waltregny D, Werbrouck P, Attwell A, Canil C, Drachenberg D, Finch D, Gleave M, Joshua AM, Klotz L, Lacombe L, Mukherjee S, Ruether D, Saad F, Venner P, Winquist E, Wood L, Borre M, Holm-Nielsen A, Iversen P, Langkilde NC, Ostri P, Rathenborg P, Taari K, Tammela T, Vaarala M, Ala-Opas M, Beuzeboc P, Bompas E, Davin JL, Delva R, Ducos B, Flechon A, Gross-Goupil M, Guillot A, Houede N, Laguerre B, Latorzeff I, Lemoulec S, Loriot Y, Oudard S, Priou F, Vignot S, Voog E, Bogemann M, Bolenz C, Hadaschik B, Hammerer P, Klotz T, Merseburger A, Miller K, Ohlmann CH, Schrader M, Stenzl A, Strolin P, Suttmann H, Wirth M, Mermershtain W, Nativ O, Ramon J, Rosenbaum E, Sella A, Bracarda S, Cerbone L, De Giorgi U, Passalacqua R, Recine F, Scagliotti G, Sternberg C, Egawa S, Fukagai T, Fukumori T, Igawa T, Kamba T, Kimura G, Kosaka T, Matsuyama H, Nakatani T, Namiki S, Nishimura K, Nishiyama T, Nonomura N, Nozawa M, Numahata K, Okegawa T, Ueda T, Uemura H, Yamanaka Y, Yokomizo A, Yonese J, Jocys G, Ulys A, de Jong I, Mulders P, van den Eertwegh A, Vrijhof E, Dobrowolski A, Jassem J, Kalinka-Warzocha E, Kmieciak R, Milecki P, Al-Shukri S, Matveev V, Novikov A, Chiong E, Lau W, Balaz V, Brezovsky M, Goncalves F, Kliment J, Mincik I, Choi YD, Chung BH, Kim CS, Kwon DD, Lee HM, Lee KH, Lee SE, Alcaraz A, Bellmunt J, Burgos F, Carles J, Domenech M, Font A, Gallardo E, Garcia-Donas Jimenez J, Gil-Bazo I, Gomez Veiga F, Gonzalez A, Andren O, Bjartell A, Damber JE, Ljungberg B, Wiklund P, Bahl A, Chowdhury S, de Bono J, Gilbert D, Hoskin P, Malik Z, McLaren D, Payne H, Pedley I, Protheroe A, Tanguay J, Waxman J, Andriole G, Appleman L, Armstrong A, Beer T, Berry W, Bolger G, Courtney K, Dorff T, Evans C, Flaig T, Fleming M, Haas N, Hall S, Hauke S, Higano C, Keane T, Khan M, Kohli M, Koletsky A, Kuzel T, McNeel D, Nazemzadeh R, Rathkopf D, Redfern C, Rettig M, Singh P, Srinivas S, Taplin ME, Vaishampayan U, Armstrong AJ, Beer TM, Higano CS, Iversen P, Sternberg CN, Tombal B, Andresen C, Martinez H, McNees A, Parli T, Pham T, Tabora K, Thomrongsith L, Zhao S., N. Engl. J. Med. 371(5), 2014
PMID: 24881730
A community effort to assess and improve drug sensitivity prediction algorithms.
Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G, Abbuehl JP, Aittokallio T, Allen J, Altman RB, Ammad-ud-din M, Balcome S, Bansal M, Battle A, Bender A, Berger B, Bernard J, Bhattacharjee M, Bhuvaneshwar K, Bieberich AA, Boehm F, Califano A, Chan C, Chen B, Chen TH, Choi J, Coelho LP, Cokelaer T, Collins JC, Costello JC, Creighton CJ, Cui J, Dampier W, Davisson VJ, De Baets B, Deshpande R, DiCamillo B, Dundar M, Duren Z, Ertel A, Fan H, Fang H, Gallahan D, Gauba R, Georgii E, Gonen M, Gottlieb A, Grau M, Gray JW, Gusev Y, Ha MJ, Han L, Harris M, Heiser LM, Henderson N, Hejase HA, Hintsanen P, Homicsko K, Honkela A, Hou JP, Hwang W, IJzerman AP, Kallioniemi O, Karacali B, Kaski S, Keles S, Kendziorski C, Khan SA, Kim J, Kim M, Kim Y, Knowles DA, Koller D, Lee J, Lee JK, Lenselink EB, Li B, Li B, Li J, Liang H, Ma J, Madhavan S, Menden MP, Mooney S, Mpindi JP, Myers CL, Newton MA, Overington JP, Pal R, Peng J, Pestell R, Prill RJ, Qiu P, Rajwa B, Sadanandam A, Saez-Rodriguez J, Sambo F, Shin H, Singer D, Song J, Song L, Sridhar A, Stock M, Stolovitzky G, Sun W, Ta T, Tadesse M, Tan M, Tang H, Theodorescu D, Toffolo GM, Tozeren A, Trepicchio W, Varoquaux N, Vert JP, Waegeman W, Walter T, Wan Q, Wang D, Wang NJ, Wang W, Wang Y, Wang Z, Wegner JK, Wennerberg K, Wu T, Xia T, Xiao G, Xie Y, Xu Y, Yang J, Yuan Y, Zhang S, Zhang XS, Zhao J, Zuo C, van Vlijmen HW, van Westen GJ., Nat. Biotechnol. 32(12), 2014
PMID: 24880487
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Marx G, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip D, Carpentier P, Luyten D, Rottey S, Van Aelst F, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, North S, Abdel-Hamid S, Colombel M, Flechon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M, Miller K, Oetzel R, Roigas J, Steuber T, Stockle M, Wirth M, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, de Reijke T, Arija J, Bellmunt J, Lopez R, Lopez-Brea M, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Berry W, Bubley G, Carney J, Chu L, Cosgriff T, Denmeade S, Deshpande H, Duchene D, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J, Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pinski J, Poiesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N, Wilding G, Wong Y, Belldegrun A, Kantoff PW, Carducci MA, Vogelzang NJ, Kelly WK, Auchus RJ, Meyers M, Rackoff W, Tran N, Yu M, Knoblauch R, Naini V, Matheny S, Maul S, Larsen J, Martin J, Wawda H, Goffredo D, Li J, Li S, Li B, Durve K, Morris MJ, Larson SM., N. Engl. J. Med. 368(2), 2012
PMID: 23228172
Regularized machine learning in the genetic prediction of complex traits.
Okser S, Pahikkala T, Airola A, Salakoski T, Ripatti S, Aittokallio T., PLoS Genet. 10(11), 2014
PMID: 25393026
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C., Lancet 377(9768), 2011
PMID: 21353695
Global cancer statistics.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., CA Cancer J Clin 61(2), 2011
PMID: 21296855
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K., Lancet Oncol. 16(4), 2015
PMID: 25743937
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O; ALSYMPCA Investigators, Brown M, Dalley D, Dickie G, Dowling A, Elison B, Francis R, Harrup R, Jackson M, Jones E, Kirkwood I, Lin M, Macfarlane D, Martin J, Marx G, Miller A, Pittman K, Pocock N, Pointon O, Roach P, Rossleigh M, Sidhom M, Swift P, Taubman K, Unger S, Woo H, Billiet I, Deconnick H, Duck L, Dumont P, Arouca P, Cabral W, Horizonte B, Caspani A, Horizonte B, Coelho B, Damiao R, Kasai E, Koff W, Moraes AA, Murad A, Horizonte B, Oliveira F, Oliveria L, Sampaio C, Sapienza M, Serrano S, Vilela J, House L, Klotz L, Kuhl J, Leung E, Patel S, Reid R, Simone D, Vitols-McKay M, Bolcak K, Buncova M, Feltl D, Hora M, Kocak I, Kopacek R, Kraft O, Myslivecek M, Pernicka J, Schraml J, Zachoval R, Monnier A, Pecking A, Priou F, Quetu F, Rudenko B, Toubeau M, Wartski M, Zanetta G, Barsegian V, Brunkhorst T, Haese A, Hampel C, Kashammer S, Keil C, Klutmann S, Kranert T, Kuczyk M, Mommsen C, Pfestroff A, Reske S, Sahlmann CO, Schrader A, Strauss A, Truss MC, von Pokrzywnitzki W, Cheng H, Kwong P, Leung A, Leung S, Liu C, Tang F, Yau T, Yuen K, Agranovich S, Ben-Yosef R, Dror Y, Golan H, Levita M, Mechlis-Frish S, Mermershtain W, Sella A, Aglietta M, Amadori D, Ariano M, Asti M, Carrara F, Messina C, Poli G, Possa M, Rossetti C, Salvo D, de Jong A, Roeleveld T, van Riel M, van Tilburg E, Vergunst H, Verhagen P, Aurebekk A, Bjering K, Boe K, Fredenfeldt T, Grovnes T, Kasti U, Klepp DO, Larsen K, Nieder C, Pedersen L, Stokkan M, Tvedt B, Chlosta P, Demkow T, Glowa B, Jarzab B, Jarzemski P, Kasprzak K, Klijer R, Kolodziejczyk A, Landwojtowicz M, Mielczarek R, Ochman P, Poniatowicz-Frasunek E, Sowa A, Staszczak , Szczodry A, Zdrojowy R, Zebrowski J, Goh A, Ng C, Tay M, Arpasova M, Balaz V, Breza J, Cano M, Cuperkova J, Cvik M, Lesko J, Mincik I, Reznak I, Spisiakova D, Aranda E, Arbizu J, Banzo J, Bello P, Carles J, Castell J, Donas G, Estorch M, Fombellida J, Perez Gracia JL, Latre J, Llarena R, Lomena F, Lopez R, Maroto P, Mellado B, Mitjavila M, Reynes G, Ruibal A, Saenz-Cusi A, Axelsson B, Backlund M, Bergstrom P, Boling B, Falkmer U, Fransson A, Kindblom J, Lagerlund M, Larsson A, Lindgren U, Matscheko G, Starck SA, Anderson P, Bahl A, Bovill R, Chakraborti P, Cox R, Cripps H, Dixit S, Fletcher C, Foley M, Gannon K, Gibbs S, Gilmore B, Graham J, Heath C, Hooper S, Ibbett D, Jenkins C, Jones I, Lawrence G, Money-Kyrle J, Monk D, Mundy J, Murby B, Pascoe S, Przeslak A, Ramachandra P, Randerson S, Richardson A, Robinson A, Scrase C, Scuffham J, Staffurth J, Stockdale A, Sundar S, Vasanthan S, Waldock P, Walton S, Yarrow S, Arredondo S, Garcia-Ramirez J, Hudes G, Lamey R, Michalski J, Mosley D, Obranovich G, Sanders R, Sandler H, Sanford R, Tomblyn M, Vade Streek P., N. Engl. J. Med. 369(3), 2013
PMID: 23863050
A community computational challenge to predict the activity of pairs of compounds.
Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y; NCI-DREAM Community, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community, Abbuehl JP, Allen J, Altman RB, Balcome S, Bansal M, Bell A, Bender A, Berger B, Bernard J, Bieberich AA, Borboudakis G, Califano A, Chan C, Chen B, Chen TH, Choi J, Coelho LP, Costello JC, Creighton CJ, Dampier W, Davisson VJ, Deshpande R, Diao L, Di Camillo B, Dundar M, Ertel A, Gallahan D, Goswami CP, Gottlieb A, Gould MN, Goya J, Grau M, Gray JW, Heiser LM, Hejase HA, Hoffmann MF, Homicsko K, Homilius M, Hwang W, Ijzerman AP, Kallioniemi O, Karacali B, Karan C, Kaski S, Kim J, Kim M, Krishnan A, Lee J, Lee YS, Lenselink EB, Lenz P, Li L, Li J, Li Y, Liang H, Mattioli M, Menden MP, Mpindi JP, Myers CL, Newton MA, Overington JP, Parkkinen J, Prill RJ, Peng J, Pestell R, Qiu P, Rajwa B, Realubit R, Sadanandam A, Saez-Rodriguez J, Sambo F, Singer D, Stolovitzky G, Sridhar A, Sun W, Tang H, Toffolo GM, Tozeren A, Troyanskaya OG, Tsamardinos I, van Vlijmen HW, Wang T, Wang W, Wegner JK, Wennerberg K, van Westen GJ, Xia T, Xiao G, Xie Y, Yang J, Yang Y, Yao V, Yuan Y, Zeng H, Zhang S, Zhao J, Zhou J, Zhong R., Nat. Biotechnol. 32(12), 2014
PMID: 25419740
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW., J. Clin. Oncol. 20(19), 2002
PMID: 12351594
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators, Ahmed T, Amin A, Arseneau J, Barth N, Bernstein G, Bracken B, Burch P, Caggiano V, Chin J, Chodak G, Chu F, Corman J, Curti B, Dawson N, Deeken JF, Dubernet T, Fishman M, Flanigan R, Gailani F, Garbo L, Gardner T, Gelmann E, George D, Godfrey T, Gomella L, Guerra M, Hall S, Hanson J, Israeli R, Jancis E, Jewett MA, Kassabian V, Katz J, Klotz L, Koeneman K, Koh H, Kratzke R, Lance R, Lech J, Leichman L, Lemon R, Liang J, Libertino J, Lilly M, Malik I, Martin SE, McCaffrey J, McLeod D, McNeel D, Miles B, Murdock M, Nabhan C, Nemunaitis J, Notter D, Pantuck A, Perrotte P, Pessis D, Petrylak D, Polikoff J, Pommerville P, Ramanathan S, Rarick M, Richards J, Rifkin R, Rohatgi N, Rosenbluth R, Santucci R, Sayegh A, Seigne J, Shapira I, Shedhadeh N, Shepherd D, Sridhar S, Stephenson R, Teigland C, Thaker N, Vacirca J, Villa L Jr, Vogelzang N, Wertheim M, Wolff JH, Wurzel R, Yang C, Young J., N. Engl. J. Med. 363(5), 2010
PMID: 20818862
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ., N. Engl. J. Med. 374(23), 2016
PMID: 27276561
Seeking the wisdom of crowds through challenge-based competitions in biomedical research.
Costello JC, Stolovitzky G., Clin. Pharmacol. Ther. 93(5), 2013
PMID: 23549146
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ., J. Clin. Oncol. 32(7), 2014
PMID: 24449231
Challenges: Crowdsourced solutions.
Bender E., Nature 533(7602), 2016
PMID: 27167394
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators., Lancet Oncol. 14(8), 2013
PMID: 23742877
Abiraterone and increased survival in metastatic prostate cancer.
Berruti A, Pia A, Terzolo M., N. Engl. J. Med. 365(8), 2011
PMID: 21864182
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators, Alasino C, Bella S, Carraro S, Geist M, Abdi E, Begbie S, Briscoe K, Davis I, Dowling A, Ganju V, Gurney H, Hovey E, Ng S, Nottage M, Rosenthal M, Stockler M, Tan T, Wong S, Young R, Krainer M, Loidl W, Machiels J, Mebis J, Renard V, Dumez H, Van Aelst F, Werbrouck P, Ellard S, Joshua A, Karakiewicz P, Lacombe L, Lattouf JB, Michels J, Mukherjee S, Ruether D, Venner P, Winquist E, Wood L, Aren O, Gonzalez P, Pastor P, Baumgaertner I, Beuzeboc P, Bompas E, Boyle H, Colombel M, Delva R, Eymard J, Gravis G, Guillot A, Houede N, Joly F, Kaphan R, Loriot Y, Oudard S, Priou F, Tartas S, Theodore C, Tourani JM, Voog E, Bogemann M, Hadaschik B, Hammerer P, Heidenreich A, Holzer W, Merseburger A, Stenzl A, Steuber T, Suttmann H, Trojan L, Wirth M, Cerbone L, Conte P, Passalacqua R, Tucci M, Gerritsen W, Jassem J, Kalinka-Warzocha E, Olubiec J, De Bruyne R, Malan J, Vorobiof D, Bellmunt J, Carles J, Duran I, Font A, Gil-Bazo I, Maroto J, Bahl A, Choudhury A, Hoskin P, James N, Jones R, Mazhar D, O'Sullivan J, Payne H, Pedley I, Protheroe A, Waxman J, Zivi A, Alexander B, Appleman L, Aragon-Ching J, Arrowsmith E, Assikis V, Beer T, Berry W, Bolger G, Bryce A, Bubley G, Chatta G, Denmeade S, Deshpande H, Dorff T, Galsky M, George D, Giudice R, Glode M, Golshayan AR, Goodman O, Graff J, Green L, Green R, Haas N, Higano C, Hutson T, Kohli M, Liu G, May J, Mendelson D, Picus J, Pili R, Posadas E, Redfern C, Rettig M, Ryan C, Scholz M, Sharifi N, Sosman J, Srinivas S, Tagawa S, Twardowski P, Vaishampayan U, Wong YN., N. Engl. J. Med. 367(13), 2012
PMID: 22894553
Crowdsourcing biomedical research: leveraging communities as innovation engines.
Saez-Rodriguez J, Costello JC, Friend SH, Kellen MR, Mangravite L, Meyer P, Norman T, Stolovitzky G., Nat. Rev. Genet. 17(8), 2016
PMID: 27418159
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G., J. Clin. Oncol. 29(16), 2011
PMID: 21483004
Data Sharing.
Longo DL, Drazen JM., N. Engl. J. Med. 374(3), 2016
PMID: 26789876
A Global, Neutral Platform for Sharing Trial Data.
Bierer BE, Li R, Barnes M, Sim I., N. Engl. J. Med. 374(25), 2016
PMID: 27168194
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.
Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Borresen-Dale AL., Sci Transl Med 5(181), 2013
PMID: 23596205
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators., Lancet 376(9747), 2010
PMID: 20888992
Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection.
Ewing AD, Houlahan KE, Hu Y, Ellrott K, Caloian C, Yamaguchi TN, Bare JC, P'ng C, Waggott D, Sabelnykova VY; ICGC-TCGA DREAM Somatic Mutation Calling Challenge participants, Kellen MR, Norman TC, Haussler D, Friend SH, Stolovitzky G, Margolin AA, Stuart JM, Boutros PC, Xi L, Dewal N, Fan Y, Wang W, Wheeler D, Wilm A, Ting GH, Li C, Bertrand D, Nagarajan N, Chen QR, Hsu CH, Hu Y, Yan C, Kibbe W, Meerzaman D, Cibulskis K, Rosenberg M, Bergelson L, Kiezun A, Radenbaugh A, Sertier AS, Ferrari A, Tonton L, Bhutani K, Hansen NF, Wang D, Song L, Lai Z, Liao Y, Shi W, Carbonell-Caballero J, Dopazo J, Lau CC, Guinney J., Nat. Methods 12(7), 2015
PMID: 25984700
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K, Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW., J. Clin. Oncol. 31(14), 2013
PMID: 23569308
Avoiding Data Dumpsters--Toward Equitable and Useful Data Sharing.
Merson L, Gaye O, Guerin PJ., N. Engl. J. Med. 374(25), 2016
PMID: 27168351
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ., J. Clin. Oncol. 21(7), 2003
PMID: 12663709
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M., Clin. Cancer Res. 13(21), 2007
PMID: 17975152
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tanimoto T, Hori A, Kami M., N. Engl. J. Med. 363(20), 2010
PMID: 21067392
Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators, Begbie S, Bonaventura A, Boyce A, Chua W, de Souza P, Davis I, Gardiner F, Guminski A, Gurney H, Hovey E, Mainwaring P, Marx G, Mathlum M, Parente P, Parnis F, Pook D, Rosenthal M, Shapiro J, Toner G, Warren M, Wong S, Woo H, Janetschek G, Krainer M, Loidl W, Schmeller N, Mebis J, Renard V, Tombal B, Van Poppel H, Waltregny D, Werbrouck P, Attwell A, Canil C, Drachenberg D, Finch D, Gleave M, Joshua AM, Klotz L, Lacombe L, Mukherjee S, Ruether D, Saad F, Venner P, Winquist E, Wood L, Borre M, Holm-Nielsen A, Iversen P, Langkilde NC, Ostri P, Rathenborg P, Taari K, Tammela T, Vaarala M, Ala-Opas M, Beuzeboc P, Bompas E, Davin JL, Delva R, Ducos B, Flechon A, Gross-Goupil M, Guillot A, Houede N, Laguerre B, Latorzeff I, Lemoulec S, Loriot Y, Oudard S, Priou F, Vignot S, Voog E, Bogemann M, Bolenz C, Hadaschik B, Hammerer P, Klotz T, Merseburger A, Miller K, Ohlmann CH, Schrader M, Stenzl A, Strolin P, Suttmann H, Wirth M, Mermershtain W, Nativ O, Ramon J, Rosenbaum E, Sella A, Bracarda S, Cerbone L, De Giorgi U, Passalacqua R, Recine F, Scagliotti G, Sternberg C, Egawa S, Fukagai T, Fukumori T, Igawa T, Kamba T, Kimura G, Kosaka T, Matsuyama H, Nakatani T, Namiki S, Nishimura K, Nishiyama T, Nonomura N, Nozawa M, Numahata K, Okegawa T, Ueda T, Uemura H, Yamanaka Y, Yokomizo A, Yonese J, Jocys G, Ulys A, de Jong I, Mulders P, van den Eertwegh A, Vrijhof E, Dobrowolski A, Jassem J, Kalinka-Warzocha E, Kmieciak R, Milecki P, Al-Shukri S, Matveev V, Novikov A, Chiong E, Lau W, Balaz V, Brezovsky M, Goncalves F, Kliment J, Mincik I, Choi YD, Chung BH, Kim CS, Kwon DD, Lee HM, Lee KH, Lee SE, Alcaraz A, Bellmunt J, Burgos F, Carles J, Domenech M, Font A, Gallardo E, Garcia-Donas Jimenez J, Gil-Bazo I, Gomez Veiga F, Gonzalez A, Andren O, Bjartell A, Damber JE, Ljungberg B, Wiklund P, Bahl A, Chowdhury S, de Bono J, Gilbert D, Hoskin P, Malik Z, McLaren D, Payne H, Pedley I, Protheroe A, Tanguay J, Waxman J, Andriole G, Appleman L, Armstrong A, Beer T, Berry W, Bolger G, Courtney K, Dorff T, Evans C, Flaig T, Fleming M, Haas N, Hall S, Hauke S, Higano C, Keane T, Khan M, Kohli M, Koletsky A, Kuzel T, McNeel D, Nazemzadeh R, Rathkopf D, Redfern C, Rettig M, Singh P, Srinivas S, Taplin ME, Vaishampayan U, Armstrong AJ, Beer TM, Higano CS, Iversen P, Sternberg CN, Tombal B, Andresen C, Martinez H, McNees A, Parli T, Pham T, Tabora K, Thomrongsith L, Zhao S., N. Engl. J. Med. 371(5), 2014
PMID: 24881730
A community effort to assess and improve drug sensitivity prediction algorithms.
Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G, Abbuehl JP, Aittokallio T, Allen J, Altman RB, Ammad-ud-din M, Balcome S, Bansal M, Battle A, Bender A, Berger B, Bernard J, Bhattacharjee M, Bhuvaneshwar K, Bieberich AA, Boehm F, Califano A, Chan C, Chen B, Chen TH, Choi J, Coelho LP, Cokelaer T, Collins JC, Costello JC, Creighton CJ, Cui J, Dampier W, Davisson VJ, De Baets B, Deshpande R, DiCamillo B, Dundar M, Duren Z, Ertel A, Fan H, Fang H, Gallahan D, Gauba R, Georgii E, Gonen M, Gottlieb A, Grau M, Gray JW, Gusev Y, Ha MJ, Han L, Harris M, Heiser LM, Henderson N, Hejase HA, Hintsanen P, Homicsko K, Honkela A, Hou JP, Hwang W, IJzerman AP, Kallioniemi O, Karacali B, Kaski S, Keles S, Kendziorski C, Khan SA, Kim J, Kim M, Kim Y, Knowles DA, Koller D, Lee J, Lee JK, Lenselink EB, Li B, Li B, Li J, Liang H, Ma J, Madhavan S, Menden MP, Mooney S, Mpindi JP, Myers CL, Newton MA, Overington JP, Pal R, Peng J, Pestell R, Prill RJ, Qiu P, Rajwa B, Sadanandam A, Saez-Rodriguez J, Sambo F, Shin H, Singer D, Song J, Song L, Sridhar A, Stock M, Stolovitzky G, Sun W, Ta T, Tadesse M, Tan M, Tang H, Theodorescu D, Toffolo GM, Tozeren A, Trepicchio W, Varoquaux N, Vert JP, Waegeman W, Walter T, Wan Q, Wang D, Wang NJ, Wang W, Wang Y, Wang Z, Wegner JK, Wennerberg K, Wu T, Xia T, Xiao G, Xie Y, Xu Y, Yang J, Yuan Y, Zhang S, Zhang XS, Zhao J, Zuo C, van Vlijmen HW, van Westen GJ., Nat. Biotechnol. 32(12), 2014
PMID: 24880487
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Marx G, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip D, Carpentier P, Luyten D, Rottey S, Van Aelst F, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, North S, Abdel-Hamid S, Colombel M, Flechon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M, Miller K, Oetzel R, Roigas J, Steuber T, Stockle M, Wirth M, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, de Reijke T, Arija J, Bellmunt J, Lopez R, Lopez-Brea M, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Berry W, Bubley G, Carney J, Chu L, Cosgriff T, Denmeade S, Deshpande H, Duchene D, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J, Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pinski J, Poiesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N, Wilding G, Wong Y, Belldegrun A, Kantoff PW, Carducci MA, Vogelzang NJ, Kelly WK, Auchus RJ, Meyers M, Rackoff W, Tran N, Yu M, Knoblauch R, Naini V, Matheny S, Maul S, Larsen J, Martin J, Wawda H, Goffredo D, Li J, Li S, Li B, Durve K, Morris MJ, Larson SM., N. Engl. J. Med. 368(2), 2012
PMID: 23228172
Regularized machine learning in the genetic prediction of complex traits.
Okser S, Pahikkala T, Airola A, Salakoski T, Ripatti S, Aittokallio T., PLoS Genet. 10(11), 2014
PMID: 25393026
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C., Lancet 377(9768), 2011
PMID: 21353695
Global cancer statistics.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., CA Cancer J Clin 61(2), 2011
PMID: 21296855
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K., Lancet Oncol. 16(4), 2015
PMID: 25743937
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O; ALSYMPCA Investigators, Brown M, Dalley D, Dickie G, Dowling A, Elison B, Francis R, Harrup R, Jackson M, Jones E, Kirkwood I, Lin M, Macfarlane D, Martin J, Marx G, Miller A, Pittman K, Pocock N, Pointon O, Roach P, Rossleigh M, Sidhom M, Swift P, Taubman K, Unger S, Woo H, Billiet I, Deconnick H, Duck L, Dumont P, Arouca P, Cabral W, Horizonte B, Caspani A, Horizonte B, Coelho B, Damiao R, Kasai E, Koff W, Moraes AA, Murad A, Horizonte B, Oliveira F, Oliveria L, Sampaio C, Sapienza M, Serrano S, Vilela J, House L, Klotz L, Kuhl J, Leung E, Patel S, Reid R, Simone D, Vitols-McKay M, Bolcak K, Buncova M, Feltl D, Hora M, Kocak I, Kopacek R, Kraft O, Myslivecek M, Pernicka J, Schraml J, Zachoval R, Monnier A, Pecking A, Priou F, Quetu F, Rudenko B, Toubeau M, Wartski M, Zanetta G, Barsegian V, Brunkhorst T, Haese A, Hampel C, Kashammer S, Keil C, Klutmann S, Kranert T, Kuczyk M, Mommsen C, Pfestroff A, Reske S, Sahlmann CO, Schrader A, Strauss A, Truss MC, von Pokrzywnitzki W, Cheng H, Kwong P, Leung A, Leung S, Liu C, Tang F, Yau T, Yuen K, Agranovich S, Ben-Yosef R, Dror Y, Golan H, Levita M, Mechlis-Frish S, Mermershtain W, Sella A, Aglietta M, Amadori D, Ariano M, Asti M, Carrara F, Messina C, Poli G, Possa M, Rossetti C, Salvo D, de Jong A, Roeleveld T, van Riel M, van Tilburg E, Vergunst H, Verhagen P, Aurebekk A, Bjering K, Boe K, Fredenfeldt T, Grovnes T, Kasti U, Klepp DO, Larsen K, Nieder C, Pedersen L, Stokkan M, Tvedt B, Chlosta P, Demkow T, Glowa B, Jarzab B, Jarzemski P, Kasprzak K, Klijer R, Kolodziejczyk A, Landwojtowicz M, Mielczarek R, Ochman P, Poniatowicz-Frasunek E, Sowa A, Staszczak , Szczodry A, Zdrojowy R, Zebrowski J, Goh A, Ng C, Tay M, Arpasova M, Balaz V, Breza J, Cano M, Cuperkova J, Cvik M, Lesko J, Mincik I, Reznak I, Spisiakova D, Aranda E, Arbizu J, Banzo J, Bello P, Carles J, Castell J, Donas G, Estorch M, Fombellida J, Perez Gracia JL, Latre J, Llarena R, Lomena F, Lopez R, Maroto P, Mellado B, Mitjavila M, Reynes G, Ruibal A, Saenz-Cusi A, Axelsson B, Backlund M, Bergstrom P, Boling B, Falkmer U, Fransson A, Kindblom J, Lagerlund M, Larsson A, Lindgren U, Matscheko G, Starck SA, Anderson P, Bahl A, Bovill R, Chakraborti P, Cox R, Cripps H, Dixit S, Fletcher C, Foley M, Gannon K, Gibbs S, Gilmore B, Graham J, Heath C, Hooper S, Ibbett D, Jenkins C, Jones I, Lawrence G, Money-Kyrle J, Monk D, Mundy J, Murby B, Pascoe S, Przeslak A, Ramachandra P, Randerson S, Richardson A, Robinson A, Scrase C, Scuffham J, Staffurth J, Stockdale A, Sundar S, Vasanthan S, Waldock P, Walton S, Yarrow S, Arredondo S, Garcia-Ramirez J, Hudes G, Lamey R, Michalski J, Mosley D, Obranovich G, Sanders R, Sandler H, Sanford R, Tomblyn M, Vade Streek P., N. Engl. J. Med. 369(3), 2013
PMID: 23863050
A community computational challenge to predict the activity of pairs of compounds.
Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y; NCI-DREAM Community, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community, Abbuehl JP, Allen J, Altman RB, Balcome S, Bansal M, Bell A, Bender A, Berger B, Bernard J, Bieberich AA, Borboudakis G, Califano A, Chan C, Chen B, Chen TH, Choi J, Coelho LP, Costello JC, Creighton CJ, Dampier W, Davisson VJ, Deshpande R, Diao L, Di Camillo B, Dundar M, Ertel A, Gallahan D, Goswami CP, Gottlieb A, Gould MN, Goya J, Grau M, Gray JW, Heiser LM, Hejase HA, Hoffmann MF, Homicsko K, Homilius M, Hwang W, Ijzerman AP, Kallioniemi O, Karacali B, Karan C, Kaski S, Kim J, Kim M, Krishnan A, Lee J, Lee YS, Lenselink EB, Lenz P, Li L, Li J, Li Y, Liang H, Mattioli M, Menden MP, Mpindi JP, Myers CL, Newton MA, Overington JP, Parkkinen J, Prill RJ, Peng J, Pestell R, Qiu P, Rajwa B, Realubit R, Sadanandam A, Saez-Rodriguez J, Sambo F, Singer D, Stolovitzky G, Sridhar A, Sun W, Tang H, Toffolo GM, Tozeren A, Troyanskaya OG, Tsamardinos I, van Vlijmen HW, Wang T, Wang W, Wegner JK, Wennerberg K, van Westen GJ, Xia T, Xiao G, Xie Y, Yang J, Yang Y, Yao V, Yuan Y, Zeng H, Zhang S, Zhao J, Zhou J, Zhong R., Nat. Biotechnol. 32(12), 2014
PMID: 25419740
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW., J. Clin. Oncol. 20(19), 2002
PMID: 12351594
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators, Ahmed T, Amin A, Arseneau J, Barth N, Bernstein G, Bracken B, Burch P, Caggiano V, Chin J, Chodak G, Chu F, Corman J, Curti B, Dawson N, Deeken JF, Dubernet T, Fishman M, Flanigan R, Gailani F, Garbo L, Gardner T, Gelmann E, George D, Godfrey T, Gomella L, Guerra M, Hall S, Hanson J, Israeli R, Jancis E, Jewett MA, Kassabian V, Katz J, Klotz L, Koeneman K, Koh H, Kratzke R, Lance R, Lech J, Leichman L, Lemon R, Liang J, Libertino J, Lilly M, Malik I, Martin SE, McCaffrey J, McLeod D, McNeel D, Miles B, Murdock M, Nabhan C, Nemunaitis J, Notter D, Pantuck A, Perrotte P, Pessis D, Petrylak D, Polikoff J, Pommerville P, Ramanathan S, Rarick M, Richards J, Rifkin R, Rohatgi N, Rosenbluth R, Santucci R, Sayegh A, Seigne J, Shapira I, Shedhadeh N, Shepherd D, Sridhar S, Stephenson R, Teigland C, Thaker N, Vacirca J, Villa L Jr, Vogelzang N, Wertheim M, Wolff JH, Wurzel R, Yang C, Young J., N. Engl. J. Med. 363(5), 2010
PMID: 20818862
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Dohner K, Schlenk RF, Dohner H, Campbell PJ., N. Engl. J. Med. 374(23), 2016
PMID: 27276561
Seeking the wisdom of crowds through challenge-based competitions in biomedical research.
Costello JC, Stolovitzky G., Clin. Pharmacol. Ther. 93(5), 2013
PMID: 23549146

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 27864015
PubMed | Europe PMC

Suchen in

Google Scholar